Loading clinical trials...
Loading clinical trials...
An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens
Conditions
Interventions
Daptomycin
Standard of Care (SOC)
Locations
30
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Children's Hospital Research Center Oakland
Oakland, California, United States
Children's Hospital of Orange County
Orange, California, United States
Rady Children's Hospital - San Diego
San Diego, California, United States
University of South Florida College of Medicine
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Start Date
July 23, 2008
Primary Completion Date
October 11, 2013
Completion Date
October 11, 2013
Last Updated
September 5, 2018
NCT03643952
NCT00761215
NCT00785200
NCT00388310
NCT00488345
NCT00257036
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions